ArticleResearch square2026
Elevated m 6 A RNA Modifications Associate with Immune Dysregulation and Cancer in People with HIV-1.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated byElevated m2026
Authors and funding
4 authors.
Funding
Abstract
backgroundN 6-methyladenosine (m 6 A) modifications of human immunodeficiency virus type 1 (HIV-1) and cellular RNA contribute to viral immune evasion and regulation of host and viral gene expression. We reported elevated RNA m 6 A levels in peripheral blood mononuclear cells (PBMCs) from HIV-1 viremic individuals compared to those on antiretroviral therapy (ART). RNA m 6 A dysregulation has been implicated in many types of cancer. However, the role of m 6 A modifications in HIV-1-associated cancers remains to be investigated. In this study, we aim to address this important question using clinical samples.
methodsWe quantified RNA m 6 A levels in PBMCs from 43 de-identified people living with HIV-1 (PLWH), comparing those with cancer (n=15) to those without cancer (n=28). We used enzyme-linked immunosorbent assay (ELISA) to measure RNA m 6 A levels in PBMCs. Using an array of reverse transcription quantitative polymerase chain reaction (RT-qPCR), we performed quantitative transcriptomic analysis of 84 IFN-I-responsive genes in PBMCs. Furthermore, we performed linear regression analyses of cellular RNA m 6 A levels with HIV-1 RNA copies and CD4 + T cell counts in peripheral blood.
resultsWe found that m 6 A levels of PBMCs were 2.8-fold higher in the cancer group and correlated with expression of m 6 A regulatory genes. Higher m 6 A levels were also associated with increased HIV-1 RNA copies and reduced CD4 + T cell counts. HIV-1 viral load in the cancer group was higher than the non-cancer group. Transcriptomic analysis of 84 IFN-I-responsive genes revealed upregulation of many pro-inflammatory and interferon-stimulated genes in PLWH with cancer.
conclusionsOur findings suggest that HIV-1 infection and cancer microenvironment-mediated m 6 A reprogramming may contribute to chronic immune activation and malignancy in PLWH. Our results also highlight a post-transcriptional mechanism linking HIV-1 persistence to cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.